- HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity2009 | First Faculty of Medicine
- Ofatumumab - new and different monoclonal anti-CD20 antibody in the treatment of multiple sclerosis2021 | Second Faculty of Medicine
- Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies2021 | First Faculty of Medicine
- Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab2014 | Faculty of Medicine in Hradec Králové
- Biological drugs in hematooncology2012 | First Faculty of Medicine
- Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment2021 | First Faculty of Medicine
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia2010 | First Faculty of Medicine, Third Faculty of Medicine
- Ofatumumab treatment of fludarabine and alemtuzumab refractory patients2012 | Faculty of Medicine in Hradec Králové
- Monoclonal Antibodies in the Treatment of Chronic Lymphocytic Leukemia in 20152015 | First Faculty of Medicine
- Ofatumumab2011 | Faculty of Medicine in Hradec Králové
- Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen2022 | Faculty of Medicine in Hradec Králové
- Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions2016 | Faculty of Medicine in Hradec Králové
- Role of rituximab in the treatment of pemphigus vulgaris2023 | First Faculty of Medicine
- Treatment of elderly and comorbid patients with chronic lymphocytic leukemia2017 | Faculty of Medicine in Hradec Králové
- Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study2016 | Publication without faculty affiliation
- Lupus nephritis and ANCA-associated vasculitis: towards precision medicine?2021 | First Faculty of Medicine
- Idelalisib in the treatment of chronic lymphocytic leukaemia2015 | First Faculty of Medicine
- Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma2023 | First Faculty of Medicine
- A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma2013 | First Faculty of Medicine
- Modern approach to the treatment of chronic lymphocytic leukemia2023 | Faculty of Medicine in Hradec Králové
- The terapeutic Options for ""Slow- go"" Patients with Chronic Lymphocytic Leukemia2015 | Faculty of Medicine in Hradec Králové
- Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group2020 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Third Faculty of Medicine
- EBV quantification in children undergoing allogeneic hematopoietic stem cell transplantation2006 | Second Faculty of Medicine
- Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study2021 | Faculty of Medicine in Hradec Králové